Literature DB >> 25390819

Repeat surgery after breast conservation for the treatment of stage 0 to II breast carcinoma: a report from the National Cancer Data Base, 2004-2010.

Lee G Wilke1, Tomasz Czechura2, Chih Wang3, Brittany Lapin3, Erik Liederbach2, David P Winchester2, Katharine Yao2.   

Abstract

IMPORTANCE: Although complete excision of breast cancer is accepted as the best means to reduce local recurrence and thereby improve survival, there is currently no standard margin width for breast conservation surgery. As a result, significant variability exists in the number of additional operations or repeat surgeries patients undergo to establish tumor-negative margins.
OBJECTIVE: To determine the patient, tumor, and facility factors that influence repeat surgery rates in US patients undergoing breast conservation surgery. DESIGN, SETTING, AND PATIENTS: Patients diagnosed as having breast cancer at a Commission on Cancer accredited center from January 1, 2004, through December 31, 2010, and identified via the National Cancer Data Base, a large observational database, were included in the analysis. A total of 316,114 patients with stage 0 to II breast cancer who underwent initial breast conservation surgery were studied. Patients who were neoadjuvantly treated or whose conditions were diagnosed by excisional biopsy were excluded. MAIN OUTCOMES AND MEASURES: Patient, tumor, and facility factors associated with repeat surgeries.
RESULTS: A total of 241,597 patients (76.4%) underwent a single lumpectomy, whereas 74,517 (23.6%) underwent at least 1 additional operation, of whom 46,250 (62.1%) underwent a completion lumpectomy and 28,267 (37.9%) underwent a mastectomy. The proportion of patients undergoing repeat surgery decreased slightly during the study period from 25.4% to 22.7% (P < .001). Independent predictors of repeat surgeries were age, race, insurance status, comorbidities, histologic subtype, estrogen receptor status, pathologic tumor size, node status, tumor grade, facility type and location, and volume of breast cancer cases. Age was inversely associated with repeat surgery, decreasing from 38.5% in patients 18 to 29 years old to 16.5% in those older than 80 years (P < .001). In contrast, larger tumor size was linearly associated with a higher repeat surgery rate (P < .001). Repeat surgeries were most common at facilities located in the Northeast region (26.5%) compared with facilities in the Mountain region, where only 18.4% of patients underwent repeat surgery (P < .001). Academic or research facilities had a 26.0% repeat surgery rate compared with a rate of 22.4% at community facilities (P < .001). CONCLUSIONS AND RELEVANCE: Approximately one-fourth of all patients who undergo initial breast conservation surgery for breast cancer will have a subsequent operative intervention. The rate of repeat surgeries varies by patient, tumor, and facility factors and has decreased slightly during the past 6 years.

Entities:  

Mesh:

Year:  2014        PMID: 25390819     DOI: 10.1001/jamasurg.2014.926

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  56 in total

1.  The Value of Repeated Breast Surgery as a Quality Indicator in Breast Cancer Care.

Authors:  Francesca Tamburelli; Riccardo Ponzone
Journal:  Ann Surg Oncol       Date:  2020-06-10       Impact factor: 5.344

Review 2.  Image-Guided Tumor Resection.

Authors:  Julia Parrish-Novak; Eric C Holland; James M Olson
Journal:  Cancer J       Date:  2015 May-Jun       Impact factor: 3.360

3.  Miniature spectral imaging device for wide-field quantitative functional imaging of the morphological landscape of breast tumor margins.

Authors:  Brandon S Nichols; Antonio Llopis; Gregory M Palmer; Samuel S McCachren; Ozlem Senlik; David Miller; Martin A Brooke; Nan M Jokerst; Joseph Geradts; Rachel Greenup; Nimmi Ramanujam
Journal:  J Biomed Opt       Date:  2017-02-01       Impact factor: 3.170

Review 4.  Update of the American Society of Breast Surgeons Toolbox to address the lumpectomy reoperation epidemic.

Authors:  Maureen P McEvoy; Jeffrey Landercasper; Himani R Naik; Sheldon Feldman
Journal:  Gland Surg       Date:  2018-12

5.  The ecosystem that powered the translation of OCT from fundamental research to clinical and commercial impact [Invited].

Authors:  Eric A Swanson; James G Fujimoto
Journal:  Biomed Opt Express       Date:  2017-02-21       Impact factor: 3.732

6.  Enhancing in vivo tumor boundary delineation with structured illumination fluorescence molecular imaging and spatial gradient mapping.

Authors:  Jessica Sun; Jessica P Miller; Deep Hathi; Haiying Zhou; Samuel Achilefu; Monica Shokeen; Walter J Akers
Journal:  J Biomed Opt       Date:  2016-08-01       Impact factor: 3.170

7.  18F-fluorodeoxyglucose specimen-positron emission mammography delineates tumour extension in breast-conserving surgery: Preliminary results.

Authors:  Gou Watanabe; M Itoh; X Duan; H Watabe; N Mori; H Tada; A Suzuki; M Miyashita; N Ohuchi; T Ishida
Journal:  Eur Radiol       Date:  2017-12-07       Impact factor: 5.315

8.  Value of MRI in medicine: More than just another test?

Authors:  Edwin J R van Beek; Christiane Kuhl; Yoshimi Anzai; Patricia Desmond; Richard L Ehman; Qiyong Gong; Garry Gold; Vikas Gulani; Margaret Hall-Craggs; Tim Leiner; C C Tschoyoson Lim; James G Pipe; Scott Reeder; Caroline Reinhold; Marion Smits; Daniel K Sodickson; Clare Tempany; H Alberto Vargas; Meiyun Wang
Journal:  J Magn Reson Imaging       Date:  2018-08-25       Impact factor: 4.813

9.  Reoperations after primary breast conserving surgery in women with invasive breast cancer in Catalonia, Spain: a retrospective study.

Authors:  J M Escribà; L Esteban; J Gálvez; M J Pla; A Melià; M Gil-Gil; R Clèries; L Pareja; X Sanz; M Bustins; J M Borrás; J Ribes
Journal:  Clin Transl Oncol       Date:  2016-09-13       Impact factor: 3.405

Review 10.  The lobar approach to breast ultrasound imaging and surgery.

Authors:  Dominique Amy; Enzo Durante; Tibor Tot
Journal:  J Med Ultrason (2001)       Date:  2015-04-02       Impact factor: 1.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.